Alnylam Pharmaceuticals
ALNY
#1145
Rank
HK$159.33 B
Marketcap
HK$1,190
Share price
-3.17%
Change (1 day)
-65.37%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2026 : HK$9.90 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is HK$9.90 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2026)

Total debt by year

Year Total debt Change
2025-12-31HK$9.94 B-1.14%
2024-12-31HK$10.06 B-1.31%
2023-12-31HK$10.19 B-1.17%
2022-12-31HK$10.31 B32.61%
2021-12-31HK$7.77 B92.53%
2020-12-31HK$4.04 B70.75%
2019-12-31HK$2.36 B907.21%
2018-12-31HK$0.23 B0.23%
2017-12-31HK$0.23 B-79.85%
2016-12-31HK$1.16 B
2007-12-31HK$52.69 M-25.84%
2006-12-31HK$71.05 M23.93%
2005-12-31HK$57.33 M2.46%
2004-12-31HK$55.96 M288.36%
2003-12-31HK$14.4 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Novartis
NVS
HK$378.98 B 3,728.08%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
HK$211.09 B 2,032.19%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
HK$21.23 B 114.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
HK$8.20 B-17.13%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
HK$10.99 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
HK$3.12 B-68.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
HK$132.37 B 1,237.09%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
HK$7.71 B-22.05%๐Ÿ‡บ๐Ÿ‡ธ USA